Sunshine Guojian Pharmaceutical (shanghai) Co., Ltd.

This study tests a new antibody drug called 611 in 124 Chinese children and adolescents aged 6 to 18 with moderate to severe atopic dermatitis (eczema). The drug targets a protein involved in inflammation. The main goals are to check safety and how the drug moves through the body…

This Phase 3 trial tested a new drug called 611 in 519 Chinese adults with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. The study compared 611 injections to a placebo over 16 weeks, measuring skin clearance a…

This study tested a new medicine called 601 against an existing drug, ranibizumab, for people with vision loss due to a blocked vein in the eye (branch retinal vein occlusion). 351 adults received injections into the eye to reduce swelling and improve sight. The goal was to see i…

This Phase 2 trial tested an experimental drug called 611 in 142 Chinese adults with moderate-to-severe COPD. Participants received either 611 or a placebo as a shot under the skin every two weeks. The study measured changes in lung function and symptom scores over 16 weeks to se…

This early-stage trial tests a single injection of the experimental drug SSGJ-626 in healthy adults aged 18 to 45. The main goal is to check for side effects and see how the drug moves through the body. Participants are randomly assigned to receive either the drug or a placebo, a…